Sutro Biopharma, Inc. (STRO)
NASDAQ: STRO · Real-Time Price · USD
15.98
+0.27 (1.72%)
Sep 25, 2026, 4:00 PM EDT - Market closed
Sutro Biopharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 45.7 | 102.48 | 62.04 | 153.73 | 67.77 | 61.88 | |
Revenue Growth | -56.26% | 65.18% | -59.64% | 126.84% | 9.52% | 44.84% |
Cost of Revenue | 144.74 | 166.42 | 252.04 | 180.43 | 137.17 | 104.4 |
Gross Profit | -99.04 | -63.93 | -190 | -26.69 | -69.4 | -42.52 |
Selling, General & Admin | 32.82 | 41.02 | 48.45 | 62.58 | 59.54 | 56 |
Operating Expenses | 32.82 | 41.02 | 48.45 | 62.58 | 59.54 | 56 |
Operating Income | -131.86 | -104.95 | -238.45 | -89.28 | -128.94 | -98.52 |
Interest Expense | -41.58 | -42.06 | -31.07 | -23.75 | -7.42 | -3.2 |
Interest & Investment Income | 6.9 | 9.25 | 18.64 | 14.51 | 3.46 | 0.58 |
Other Non Operating Income (Expenses) | - | - | -6.32 | - | - | 0.06 |
EBT Excluding Unusual Items | -166.54 | -137.76 | -257.2 | -98.52 | -132.91 | -101.08 |
Merger & Restructuring Charges | -14.19 | -53.42 | - | - | - | - |
Gain (Loss) on Sale of Investments | - | - | 32.1 | 9.92 | 16.2 | -4.45 |
Pretax Income | -180.73 | -191.18 | -225.1 | -88.6 | -116.7 | -105.54 |
Income Tax Expense | -0.1 | -0.09 | 2.36 | 18.19 | 2.5 | - |
Net Income | -180.64 | -191.09 | -227.46 | -106.79 | -119.2 | -105.54 |
Net Income to Common | -180.64 | -191.09 | -227.46 | -106.79 | -119.2 | -105.54 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 12 | 8 | 8 | 6 | 5 | 5 |
Shares Outstanding (Diluted) | 12 | 8 | 8 | 6 | 5 | 5 |
Shares Change | 38.81% | 9.84% | 28.59% | 18.57% | 10.02% | 41.59% |
EPS (Basic) | -15.47 | -22.49 | -29.40 | -17.75 | -23.49 | -22.88 |
EPS (Diluted) | -15.47 | -22.49 | -29.40 | -17.75 | -23.49 | -22.88 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -145.62 | -178.93 | -194.64 | -115.93 | -4.31 | -97 |
Free Cash Flow Per Share | -12.47 | -21.06 | -25.16 | -19.27 | -0.85 | -21.03 |
Gross Margin | -216.71% | -62.38% | - | -17.36% | -102.40% | -68.71% |
Operating Margin | -288.52% | -102.41% | -384.33% | -58.07% | -190.26% | -159.22% |
Profit Margin | -395.25% | -186.45% | -366.62% | -69.47% | -175.89% | -170.55% |
Free Cash Flow Margin | -318.63% | -174.59% | -313.72% | -75.41% | -6.36% | -156.76% |
EBITDA | -125.8 | -97.63 | -231.24 | -82.46 | -123.25 | -93.68 |
EBITDA Margin | -275.25% | -95.26% | - | -53.64% | -181.86% | -151.39% |
D&A For EBITDA | 6.06 | 7.32 | 7.22 | 6.82 | 5.69 | 4.84 |
EBIT | -131.86 | -104.95 | -238.45 | -89.28 | -128.94 | -98.52 |
EBIT Margin | -288.52% | -102.41% | - | -58.07% | -190.26% | -159.22% |